title: Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement.
abstract: Ustekinumab is a fully human monoclonal antibody targeting the common p40 subunit shared by interleukin (IL)-12 and IL-23. Ustekinumab prevents the interaction of IL-12 and IL-23 with their cell surface receptors, and thus blocks T helper (Th)-1 IL-12 and Th-17 IL-23 inflammatory pathways. Ustekinumab has been evaluated in the treatment of various chronic immune-mediated diseases including, psoriasis, psoriatic arthritis, Crohn's disease, and multiple sclerosis. It led to a rapid and durable improvement in psoriasis area and severity index in patients with moderate to severe psoriasis. Ustekinumab also improved joint symptoms of psoriatic arthritis. Results in Crohn's disease were more mitigated, albeit with a symptomatic improvement in patients refractory to tumor necrosis factor-α inhibitors. Ustekinumab did not reduce the number of magnetic resonance imaging brain lesions in multiple sclerosis. The most common adverse events to have been observed during clinical trials are mild in intensity, and include respiratory tract infections, nasopharyngitis, headaches, and injection site reactions. A pooled analysis of clinical trial data indicated no specific patterns of infection or malignancy under long-term ustekinumab administration. Ustekinumab is easy to use, has a comfortable therapeutic regimen, improves quality of life in patients, and thus appears to be an attractive biological treatment that is adapted and accepted by patients with moderate to severe psoriasis.
authors: Clinical Investigation Center - Biotherapy CBT-506, University Hospital of Besançon, Besançon, France ; Clinical Investigation Center - Biotherapy CBT-506, University Hospital of Besançon, Besançon, France ; Clinical Investigation Center - Biotherapy CBT-506, University Hospital of Besançon, Besançon, France ; Clinical Investigation Center - Biotherapy CBT-506, University Hospital of Besançon, Besançon, France.
authors: Eric
authors: E
authors: Toussirot
authors: Fabrice
authors: F
authors: Michel
authors: Matthieu
authors: M
authors: Béreau
authors: Delphine
authors: D
authors: Binda
keywords: IL-23; autoimmune diseases; psoriasis; quality of life
references: N Engl J Med. 2009 Aug 27;361(9):888-98
references: 19710487
references: Inflamm Allergy Drug Targets. 2009 Mar;8(1):40-52
references: 19275692
references: Immunology. 2012 Feb;135(2):112-24
references: 22044352
references: J Am Acad Dermatol. 2012 May;66(5):742-51
references: 21978572
references: J Rheumatol. 1998 Aug;25(8):1544-52
references: 9712099
references: Clin Biochem. 2006 Feb;39(2):119-25
references: 16386240
references: Semin Immunol. 2007 Dec;19(6):372-6
references: 18319054
references: Br J Dermatol. 2010 Jan;162(1):137-46
references: 19903183
references: N Engl J Med. 2012 Oct 18;367(16):1519-28
references: 23075178
references: Inflamm Allergy Drug Targets. 2012 Apr;11(2):159-68
references: 22280236
references: Microbes Infect. 2009 Apr;11(5):625-30
references: 19371791
references: J Exp Med. 2004 Jan 5;199(1):125-30
references: 14707118
references: Therap Adv Gastroenterol. 2010 Sep;3(5):321-8
references: 21180612
references: Immunology. 2011 Sep;134(1):8-16
references: 21726218
references: Dermatology. 2012;225(1):14-7
references: 22890275
references: J Am Acad Dermatol. 2010 Sep;63(3):457-65
references: 20462664
references: N Engl J Med. 2007 Feb 8;356(6):580-92
references: 17287478
references: J Clin Invest. 2006 May;116(5):1218-22
references: 16670765
references: Lancet. 2009 Feb 21;373(9664):633-40
references: 19217154
references: J Exp Med. 2005 Jan 17;201(2):233-40
references: 15657292
references: Ann N Y Acad Sci. 2009 Dec;1182:97-110
references: 20074279
references: Gastroenterology. 2007 Jun;132(7):2359-70
references: 17570211
references: BioDrugs. 2005;19(1):47-57
references: 15691217
references: Br J Dermatol. 2013 Jan;168(1):210-2
references: 23278559
references: Lancet. 2008 May 17;371(9625):1675-84
references: 18486740
references: Nature. 2003 Feb 13;421(6924):744-8
references: 12610626
references: J Eur Acad Dermatol Venereol. 2011 Jul;25(7):851-7
references: 21521375
references: J Eur Acad Dermatol Venereol. 2013 May;27(5):622-7
references: 22404103
references: Lancet. 2008 May 17;371(9625):1665-74
references: 18486739
references: Drugs. 2011 Sep 10;71(13):1733-53
references: 21902296
references: Gut. 2003 Jan;52(1):65-70
references: 12477762
references: J Am Acad Dermatol. 2012 May;66(5):731-41
references: 21930328
references: J Clin Invest. 2006 May;116(5):1317-26
references: 16670771
references: Arthritis Res Ther. 2008;10(2):206
references: 18466633
references: MAbs. 2009 May-Jun;1(3):216-21
references: 20069753
references: Lancet Neurol. 2008 Sep;7(9):796-804
references: 18703004
references: Clin Gastroenterol Hepatol. 2008 Jun;6(6):644-53
references: 18550004
references: N Engl J Med. 2010 Jan 14;362(2):118-28
references: 20071701
references: Am J Clin Dermatol. 2011 Apr 1;12(2):113-25
references: 21348542
references: Curr Opin Immunol. 2006 Dec;18(6):670-5
references: 17010592
references: Gastroenterology. 2008 Oct;135(4):1130-41
references: 18706417